Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-30

Study Completion Date

2024-03-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out if the study drugs nivolumab, albumin- bound paclitaxel, paricalcitol, cisplatin, and gemcitabine given together are safe and effective when combined to treat advanced pancreatic cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

NCT02570711

Metastatic Pancreatic Cancer

TERMINATED PHASE2

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

NCT03496662

Pancreatic Ductal Adenocarcinoma

COMPLETED PHASE1/PHASE2

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

NCT06423326

Borderline Resectable Pancreatic Ductal Adenocarcinoma Resectable Pancreatic Adenocarcinoma Stage I Pancreatic Cancer AJCC v8 +2 more

RECRUITING PHASE2

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

NCT07226856

Metastatic Pancreatic Adenocarcinoma Recurrent Pancreatic Adenocarcinoma Stage IV Pancreatic Cancer AJCC v8

RECRUITING PHASE2

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

NCT03970252

Borderline Resectable Pancreatic Adenocarcinoma Resectable Pancreatic Ductal Adenocarcinoma

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

single arm

open label using combination therapy

Group Type OTHER

Nivolumab

Intervention Type DRUG

Nivolumab 240mg 240 mg as a 60 minute infusion on days 1, 15, 29 per 42 day cycle

Albumin-bound paclitaxel

Intervention Type DRUG

125 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle

Paricalcitol

Intervention Type DRUG

25 micrograms IV on days 1,4,8,12,15,18,22,26,29,32,36,39 (+/-1 day allowed for dosing per 42 day cycle

Cisplatin

Intervention Type DRUG

25 mg/m2 over 60 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle

Gemcitabine

Intervention Type DRUG

1000 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nivolumab

Nivolumab 240mg 240 mg as a 60 minute infusion on days 1, 15, 29 per 42 day cycle

Intervention Type DRUG

Albumin-bound paclitaxel

125 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle

Intervention Type DRUG

Paricalcitol

25 micrograms IV on days 1,4,8,12,15,18,22,26,29,32,36,39 (+/-1 day allowed for dosing per 42 day cycle

Intervention Type DRUG

Cisplatin

25 mg/m2 over 60 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle

Intervention Type DRUG

Gemcitabine

1000 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Opdivo Abraxane Zemplar Platinol Gemzar

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥18 years of age .
2. Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma.
3. Capable of providing informed consent and complying with Trial procedures.
4. Karnofsky Performance Status (KPS) of ≥ 70%.
5. Life expectancy ≥ 12 weeks.
6. Measurable tumor lesions according to RECIST 1.1 criteria.
7. Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating. Both male and female patients of reproductive potential must agree to use a reliable method of birth control during the study.

Exclusion Criteria

1. Patients must have received no previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease. Prior treatments in the adjuvant setting with gemcitabine and/or 5-FU (5-Fluorouracil) or gemcitabine administered as a radiation sensitizer are allowed, provided at least 6 months have elapsed since completion of the last dose and no lingering toxicities are present.
2. Palliative surgery and/or radiation treatment less than 4 weeks prior to initiation of study treatment.
3. Exposure to any investigational agent within 4 weeks prior to initiation of study treatment.
4. Evidence of central nervous system (CNS) metastasis (negative imaging study, if clinically indicated, within 4 weeks of Screening Visit).
5. History of other malignancies (except cured basal cell carcinoma, superficial bladder cancer or carcinoma in situ of the cervix) unless documented free of cancer for ≥5 years.
6. Laboratory values: Screening serum creatinine \> upper limit of normal (ULN); total bilirubin \> (ULN); alanine aminotransferase (ALT) and Aspartate transaminase (AST) ≥ 2.5 ULN or ≥ 5.0×ULN if liver metastases are present; absolute neutrophil count \<1,500/mm3, platelet concentration \<100,000/mm3, hematocrit level \<27% for females or \<30% for males, or coagulation tests (prothrombin time \[PT\], partial thromboplastin time \[PTT\], International Normalized Ratio \[INR\]) \>1.5×ULN unless on therapeutic doses of warfarin.
7. Current, serious, clinically significant cardiac arrhythmias as determined by the investigator.
8. History of HIV infection or active or chronic hepatitis B or C.
9. Active, clinically significant serious infection requiring treatment with antibiotics, anti-virals or anti-fungals.
10. Major surgery within 4 weeks prior to initiation of study treatment.
11. Any condition that might interfere with the patient's participation in the study or in the evaluation of the study results.
12. Any condition that is unstable and could jeopardize the patient's participation in the study.
13. Patient has a transplanted organ.
14. Patients with a history of autoimmune disease.
15. Prior Programmed cell death protein-1 (PD-1) or Programmed death-ligand-1 (PD-L1) therapy.
16. Patients taking any chemo or immunosuppressive steroids (equivalent to \> 20 mg hydrocortisone per day).
17. Patients cannot have \> Grade 1 pre-existing peripheral neuropathy (per CTCAE).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No